Conavi Medical Corp. (TSXV:CNVI)
0.1800
-0.0100 (-5.26%)
Aug 20, 2026, 3:56 PM EST
Conavi Medical Balance Sheet
Financials in millions CAD. Fiscal year is October - September.
Millions CAD. Fiscal year is Oct - Sep.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 |
Cash & Equivalents | 4.49 | 5.84 | 0.44 | 14.17 | 4.59 |
Cash & Short-Term Investments | 4.49 | 5.84 | 0.44 | 14.17 | 4.59 |
Cash Growth | 333.69% | 1239.68% | -96.92% | 208.96% | - |
Accounts Receivable | 0.35 | 0.41 | 0.67 | 0.73 | 0.23 |
Other Receivables | 0.47 | 0.27 | 0.27 | 0.29 | 0.47 |
Receivables | 0.81 | 0.67 | 0.94 | 1.02 | 0.69 |
Inventory | 0.08 | 0.34 | 1.61 | 2.8 | 2.76 |
Prepaid Expenses | 4.94 | 1.42 | 0.55 | 1.18 | 0.55 |
Total Current Assets | 10.32 | 8.27 | 3.53 | 19.16 | 8.59 |
Property, Plant & Equipment | 1.74 | 2.02 | 2.74 | 3.37 | 3.91 |
Other Intangible Assets | 2.25 | 2.16 | 2.3 | 2.29 | 2.44 |
Total Assets | 14.31 | 12.44 | 8.56 | 24.82 | 14.94 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 |
Accounts Payable | 4.43 | 2.91 | 6 | 3.55 | 1.63 |
Short-Term Debt | - | - | 21.29 | - | - |
Current Portion of Long-Term Debt | 0.86 | 1.11 | 0.51 | 1.05 | 1 |
Current Portion of Leases | 0.44 | 0.8 | 0.26 | 0.23 | 0.19 |
Current Unearned Revenue | 0.52 | 0.61 | 0.14 | 0.36 | 0.02 |
Other Current Liabilities | 1.13 | 2.79 | - | - | - |
Total Current Liabilities | 7.37 | 8.21 | 28.19 | 5.18 | 2.84 |
Long-Term Debt | 16.38 | 17.27 | 60.11 | 51.87 | 29.19 |
Long-Term Leases | 0.54 | 0.73 | 1 | 1.26 | 1.49 |
Long-Term Unearned Revenue | 4 | 4.26 | 5.09 | 5.22 | 5.38 |
Total Liabilities | 28.29 | 30.47 | 94.39 | 63.53 | 38.9 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 |
Common Stock | 137.32 | 126.79 | 17.55 | 17.54 | 17.54 |
Additional Paid-In Capital | 17.12 | 16.23 | 20.69 | 24.23 | 12.41 |
Retained Earnings | -174.49 | -167 | -146.49 | -102.87 | -76.78 |
Comprehensive Income & Other | 6.08 | 5.95 | 4 | 3.98 | 3.25 |
Total Common Equity | -13.97 | -18.03 | -104.24 | -57.12 | -43.58 |
Shareholders' Equity | -13.97 | -18.03 | -85.83 | -38.71 | -23.96 |
Total Liabilities & Equity | 14.31 | 12.44 | 8.56 | 24.82 | 14.94 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 |
Total Debt | 18.22 | 19.91 | 83.18 | 54.41 | 31.88 |
Net Cash (Debt) | -13.72 | -14.07 | -82.74 | -40.24 | -27.29 |
Net Cash Growth | - | - | - | - | - |
Net Cash Per Share | -0.17 | -0.24 | -13.43 | -6.54 | -4.43 |
Filing Date Shares Outstanding | 103.49 | 76.75 | 44.25 | 6.16 | 6.16 |
Total Common Shares Outstanding | 103.49 | 76.75 | 6.16 | 6.16 | 6.16 |
Working Capital | 2.95 | 0.06 | -24.67 | 13.98 | 5.75 |
Book Value Per Share | -0.14 | -0.23 | -16.92 | -9.28 | -7.08 |
Tangible Book Value | -16.23 | -20.18 | -106.54 | -59.41 | -46.02 |
Tangible Book Value Per Share | -0.16 | -0.26 | -17.29 | -9.65 | -7.48 |
Machinery | 3.83 | 3.79 | 4.25 | 4.34 | 4.47 |
Leasehold Improvements | 1.15 | 1.15 | 1.15 | 1.12 | 1.09 |